Improved Acute Graft-versus Host Disease (aGVHD) and Progression Free Survival with Post-Transplant Cyclophosphamide in AML/MDS Patients (pts) with Prior CTLA-4 or PD-1 Blockade

cyclophosphamide, stem cell transplant, nivolumab, ipilimumab, AML
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research

Related Links:

ConclusionsrAML remains a clinical challenge. Genetic variability in outcomes was observed. A majority of patients with inv(16) were successfully salvaged post relapse while patients with 11q23 rearrangement had a poor prognosis. Only a third of those with t(8;21) rAML survived. Better access to SCT in HIDC is needed.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusions: This is the largest single centre data on outcomes of various haematological malignancies from India. This real world data identifies areas which need further attention to improve outcomes.
Source: Indian Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
Curry J, Featherston S, Foglesong J, Shoberu B, Gulbis A, Mireles ME, Hafemeister L, Nguyen C, Kapoor N, Rezvani K, Neelapu SS, Shpall EJ, Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network Abstract In 2017, an autologous chimeric antigen receptor (CAR) T cell therapy indicated for children and young adults with relapsed and/or refractory CD19+ acute lymphoblastic leukaemia became the first gene therapy to be approved in the USA. This innovative form of cellular immunotherapy has been associated with remarkable response rates but is also associated with unique and often severe toxicities, which ...
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Tags: Nat Rev Clin Oncol Source Type: research
Publication date: Available online 4 August 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Kiyomi Mashima, Iekuni Oh, Takashi Ikeda, Yumiko Toda, Shoko Ito, Kento Umino, Daisuke Minakata, Hirofumi Nakano, Kaoru Morita, Ryoko Yamasaki, Yasufumi Kawasaki, Miyuki Sugimoto, Chihiro Yamamoto, Masahiro Ashizawa, Shin-Ichiro Fujiwara, Kaoru Hatano, Kazuya Sato, Ken Omine, Kazuo Muroi, Yoshinobu KandaAbstractBackgroundWT1 mRNA expression is a universal marker of MRD in patients with acute myeloid leukemia (AML). The aim of this retrospective study was to evaluate the ability of serial measurement of peripheral blood ...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Hematopoietic stem cell transplantation (HSCT) represents a curative treatment for various hematological disorders. As the main component in various host conditioning regimens for HSCT, total body irradiation (TBI) is still commonly used in the treatment for multiple myeloma, lymphoma and acute lymphoblastic leukemia. But it can also cause negative effects on the transplanted HSCs. We have previously demonstrated an acute negative bystander effect of irradiated recipients on transplanted mouse HSCs (Shen H et  al, Blood 2012).
Source: Experimental Hematology - Category: Hematology Authors: Source Type: research
Acute kidney injury (AKI) is a common complication in cancer patients and occurs in up to 30% of patients during their disease course. Multiple myeloma, leukemia/lymphoma, renal cell carcinoma, and hematopoietic stem cell transplantation are commonly associated with the development of AKI.07/19/2018
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news
Publication date: Available online 17 July 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Wasithep Limvorapitak, Michael Barnett, Donna Hogge, Donna Forrest, Thomas Nevill, Sujaatha Narayanan, Maryse Power, Stephen Nantel, Raewyn Broady, Kevin Song, Cynthia Toze, Yasser Abou Mourad, Heather Sutherland, Alina Gerrie, Jennifer White, David SanfordAbstract (245 word of 250 words recommended)IntroductionOptimal post-remission therapy (PRT) for intermediate risk acute myeloid leukemia (AML) remains an area of ongoing research. We aimed to retrospectively compare outcomes following autoSCT with allogeneic SCT (allo...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Survival of adult patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) remains dismal as they are often resistant to multiple salvage chemotherapy regimens. The recent approvals of novel agents, including the bispecific T-cell engager blinatumomab, the antibody-drug conjugate inotuzumab ozogamicin, and chimeric antigen receptor T-cell products, are changing the landscape of B-cell (B)-ALL, but little progress has been made in R/R T-cell (T)-ALL.1-4 Allogenic stem cell transplantation (allo-SCT) is the only potentially curative option but requires achievement of complete remission (CR) before transplant.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Case Report Source Type: research
Abstract Acute kidney injury (AKI) is a common complication in cancer patients and occurs in up to 30% of patients during their disease course. Multiple myeloma, leukemia/lymphoma, renal cell carcinoma, and hematopoietic stem cell transplantation are commonly associated with the development of AKI. Drugs used to treat various malignancies are also a common and notable cause of AKI in this population. Nephrology consultation is important to ensure proper and rapid diagnosis, as well as appropriate therapy and follow-up. In particular, knowledge of the nephrotoxicity of the various anticancer regimens employed is cr...
Source: Oncology (Williston Park, N.Y.) - Category: Cancer & Oncology Authors: Tags: Oncology (Williston Park) Source Type: research
Publication date: July 2018Source: Clinical Lymphoma Myeloma and Leukemia, Volume 18, Issue 7Author(s): Nicholas J. Short, Hagop Kantarjian, Ching-Hon Pui, Anthony Goldstone, Elias JabbourAbstractThe widespread adoption of Bcr–Abl-directed tyrosine kinase inhibitors (TKIs) into first-line regimens for patients with Philadelphia chromosome (Ph)-positive (Ph+) acute lymphoblastic leukemia (ALL) has revolutionized the outcomes of patients with this disease. Whereas Ph+ ALL was historically associated with cure rates of 
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Acute Leukemia | Leukemia | Lymphoma | Myeloma | Stem Cell Therapy | Stem Cells | Transplants | Yervoy